Open Orphan PLC - Interim Results for 6 months ended 30 June 2019
("Open Orphan" or the "Company")
Interim Results for 6 months ended
Open Orphan, a European-focused, rare and orphan drug consulting services platform, announces its interim results for the six months ended
Reported results, based on IFRS accounting rules, reflect those of Open Orphan DAC while the Balance Sheet as of end
Financial Highlights:
· Placing of GBP
· Revenue of
· EBITDA Loss of -
· Operating Loss of -
· Cash and cash equivalents of
· Post completion of reverse takeover, continued reduction in overheads delivering cost efficiencies
o Increased staff utilisation
o Strong pipeline of potential work
o Targeting profitable growth and a return to profitability in 2020
Operational Highlights:
· Transformational reverse takeover of
o
o Identified an extensive pipeline of target acquisitions primarily in the regulatory approval, reimbursement and product launch
· Venn being successfully right-sized with reductions in overheads and in the cash burn rate
· Open Orphan Services continues to develop a pipeline of acquisitions to complement our current offering and has an ambition to complete an acquisition before the year end
· Development of the Open Orphan Genomic Health Data platform targeting patient advocacy groups to help source rare disease patient genomic data - companies approached, and early adopters expected to be announced in the second half of the year.
· Open Orphan's second digital data platform is advancing and building a platform for growth
"The combination of Venn and Open Orphan has given us a strong platform to build a full-service, high margin consultancy to offer services to the fast-growing orphan drug market right across
We are well positioned for future growth and there a number of reasons for the team and shareholders to be excited as we look into the future."
Conference call for sell-side analysts and investors
The Company will hold a conference call for sell-side analysts and investors at
Participant dial-in numbers
|
Dial in number |
Access PIN |
|
United Kingdom Toll-Free: 08003589473 |
35437628# |
|
United Kingdom Toll: +44 3333000804 |
35437628# |
|
Republic of Ireland Toll: +353 14311252 |
35437628# |
|
Republic of Ireland Toll-Free: 1800948241 |
35437628# |
URL for international dial in numbers: http://events.arkadin.com/ev/docs/NE_W2_TF_Events_International_Access_List.pdf
Enquiries:
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Notes to Editors:
Chairman's Statement
Introduction
The first half of 2019 saw the transformational reverse takeover of
Financial Results
The reported interim results reflect the six months of Open Orphan DAC following its reverse takeover of
The results of
On a reported basis reflecting IFRS accounting rules for reverse acquisitions, service fee income for the first six months of 2019 was
In June, Open Orphan successfully completed a placing, raising GBP£4.5 million. The placing positions the Company to take full advantage of the platform created from the combination of
Operational Review
Open Orphan was founded in
The reverse takeover of Venn by Open Orphan was the first step in Open Orphan Services strategy of consolidating the European orphan pharma services business. The orphan drug consulting space in
Venn has historically been loss-making due to its under-utilisation of staff. Post-completion of the reverse takeover on the 28th of June, the Directors have undertaken initiatives to resolve staff under-utilisation and increase operational efficiency. In addition, overheads, including the excessive office space and office facilities, are being significantly reduced through the leasing of surplus office space through sublets to third parties. Furthermore, the cash burn rate has been significantly reduced through a clear strategic focus on operational efficiencies. The action taken to make Venn more efficient is expected to result in growth and return to profitability in 2020.
Since the reverse takeover, Open Orphan has created two digital data access platforms. The aim of Open Orphan's digital platforms is to develop, in a low-cost manner, one of
The Genomic Health Data Platform has identified and begun establishing a patient health data platform, with a focus on orphan diseases. This is intended to be established in partnership with a number of patient advocacy groups on a revenue share basis to encourage patients with rare and orphan conditions to share their health data. In the second half of the year, it is the ambition of Open Orphan to bring onboard early adopter pharmaceutical companies and early adopter patient advocacy groups to the platform to help the Company source patient genomic data with the Company encouraged by early feedback.
The Open Orphan Virtual Rep platform enables pharmaceutical companies to engage over 4,000 key opinion leaders and physicians across
In June, we were pleased to appoint
As noted in the Admission Document the Company is undertaking an active search for a CFO to join the Board. Post the period end the Company has appointed
Outlook
We have a clear growth strategy targeting the fast-growing market for orphan drugs. The management team and Board have a strong track record and we are confident in our abilities to generate significant shareholder returns. We look forward to updating our shareholders on the exciting acquisition pipeline, the signing up of early adopter pharmaceutical companies and early adopter patient advocacy groups to the Genomic Health Data platform and our growth in the fragmented orphan drug services market in
Chairman
Consolidated Statement of Comprehensive Income
For the six months ended
|
|
|
Unaudited |
|
Unaudited |
|
Audited |
|
|
|
6 months ended |
|
6 months ended |
|
|
|
|
|
30 June |
|
30 June |
|
31 December |
|
|
|
2019 |
|
2018 |
|
2018 |
|
|
|
€'000 |
|
€'000 |
|
€'000 |
|
Continuing operations |
|
|
|
|
|
|
|
Revenue |
|
- |
|
- |
|
- |
|
Administrative expenses |
|
(179) |
|
(451) |
|
(1,611) |
|
Operating (loss)/profit |
|
(179) |
|
(451) |
|
(1,611) |
|
Depreciation and amortisation |
|
- |
|
|
|
- |
|
EBITDA before exceptional items |
|
(179) |
|
(451) |
|
(1,611) |
|
|
|
|
|
|
|
|
|
Reverse Acquisition Cost |
|
(796) |
|
- |
|
- |
|
Finance income |
|
|
|
- |
|
- |
|
Finance costs |
|
(250) |
|
(12) |
|
(45) |
|
Loss before income tax |
|
(1,225) |
|
(463) |
|
(1,656) |
|
Income tax credit |
|
- |
|
- |
|
- |
|
Loss for the period |
|
(1,225) |
|
(463) |
|
(1,656) |
|
Loss attributable |
|
|
|
|
|
|
|
Owners of the parent |
|
(1,225) |
|
(463) |
|
(1,656) |
|
Loss for the period |
|
(1,225) |
|
(463) |
|
(1,656) |
|
Currency translation differences |
|
- |
|
- |
|
- |
|
Total comprehensive loss for the period |
|
(1,225) |
|
(463) |
|
(1,656) |
|
Earnings per share from continuing operations attributable to the owners of the parent during the period (see note 2)
|
|
|
|
|
||
|
Basic and diluted (loss) per ordinary share |
|
€ Cent |
|
€ Cent |
|
€ Cent |
|
|
|
|
|
|
|
|
|
From continuing operations |
|
(1.65) |
|
(219.73) |
|
(785.29) |
|
From (loss) for the year |
|
(1.65) |
|
(219.73) |
|
(785.29) |
|
|
|
|
|
|
|
|
Consolidated Statement of Financial Position
As at
|
|
|
Unaudited |
|
Unaudited |
|
Audited |
|
|
|
As at |
|
As at |
|
As at |
|
|
|
30 June |
|
30 June |
|
31 December |
|
|
|
2019 |
|
2018 |
|
2018 |
|
|
|
€'000 |
|
€'000 |
|
€'000 |
|
Assets |
|
|
|
|
|
|
|
Non-current assets |
|
|
|
|
|
|
|
Property, plant and equipment |
|
266 |
|
- |
|
1 |
|
Intangible assets |
|
3,758 |
|
- |
|
- |
|
Right-of-use leased assets |
|
1,808 |
|
|
|
|
|
Investments |
|
31 |
|
- |
|
- |
|
Total non-current assets |
|
5,863 |
|
- |
|
1 |
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
Trade and other receivables |
|
5,669 |
|
46 |
|
36 |
|
Income tax recoverable |
|
10 |
|
- |
|
- |
|
Assets held for sale |
|
702 |
|
- |
|
- |
|
Cash and cash equivalents |
|
5,070 |
|
583 |
|
165 |
|
Total current assets |
|
11,451 |
|
629 |
|
201 |
|
Total assets |
|
17,314 |
|
629 |
|
202 |
|
|
|
|
|
|
|
|
|
Equity attributable to owners |
|
|
|
|
|
|
|
Share capital |
|
371 |
|
- |
|
- |
|
Share premium account |
|
18,973 |
|
- |
|
- |
|
Group re-organisation reserve |
|
(541) |
|
- |
|
- |
|
Reverse acquisition reserve |
|
(7,621) |
|
- |
|
- |
|
Share Option and Warrant Reserve |
|
238 |
|
|
|
|
|
Other reserve |
|
(34) |
|
- |
|
- |
|
Foreign currency reserves |
|
(44) |
|
- |
|
- |
|
Retained earnings |
|
(2,881) |
|
(765) |
|
(1,656) |
|
Total equity |
|
8,461 |
|
(765) |
|
(1,656) |
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
Non-current liabilities |
|
|
|
|
|
|
|
Lease Liabilities |
|
1,408 |
|
- |
|
- |
|
Borrowings |
|
1,748 |
|
1,215 |
|
- |
|
Total non-current liabilities |
|
3,156 |
|
1,215 |
|
- |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Trade and other payables |
|
4,755 |
|
179 |
|
498 |
|
Lease Liabilities |
|
534 |
|
|
|
|
|
Deferred taxation |
|
201 |
|
- |
|
- |
|
Borrowings |
|
207 |
|
- |
|
1,360 |
|
Total current liabilities |
|
5,697 |
|
179 |
|
1,858 |
|
Total liabilities |
|
8,853 |
|
1,394 |
|
1,858 |
|
Total equity and liabilities |
|
17,314 |
|
629 |
|
202 |
Consolidated Statement of Cash Flows
For the 6 months ended
|
|
|
Unaudited |
Unaudited |
Audited |
|
|
|
6 months ended |
6 months ended |
to |
|
|
|
30 June |
30 June |
31 December |
|
|
|
2019 |
2018 |
2018 |
|
|
|
€'000 |
€'000 |
€'000 |
|
Cash Flow from operations |
|
|
|
|
|
Loss before income tax - continuing operations |
|
(1,225) |
(463) |
(1,656) |
|
Adjustments: |
|
|
|
|
|
- Depreciation & Amortisation |
|
- |
- |
- |
|
- Net finance costs |
|
250 |
12 |
45 |
|
Changes in working capital |
|
|
|
|
|
- Trade and other receivables |
|
(22) |
(17) |
(36) |
|
- Trade and other payables |
|
552 |
24 |
497 |
|
Cash used in operations |
|
(445) |
(444) |
(1,150) |
|
Interest paid |
|
(38) |
(12) |
(45) |
|
Income tax received/(paid) |
|
- |
- |
- |
|
Net cash (used) in operating activities |
|
(483) |
(456) |
(1,195) |
|
|
|
|
|
|
|
Cash flow from investing activities |
|
|
|
|
|
Investment in subsidiary |
|
42 |
- |
- |
|
Purchase of property, plant and equipment (PPE) |
|
- |
- |
- |
|
Interest received |
|
- |
- |
- |
|
Net cash used in investing activities |
|
42 |
- |
- |
|
|
|
|
|
|
|
Cash flow from financing activities |
|
|
|
|
|
Proceeds from public placing on |
|
5,025 |
|
|
|
Issuance of ordinary shares |
|
1,543 |
- |
- |
|
Convertible Debentures Issued or converted |
|
(1,010) |
|
1,360 |
|
Conversion premium on Convertible Debentures |
|
(212) |
|
|
|
Short Term Loan Repaid |
|
|
(200) |
(200) |
|
Short Term Loan received |
|
- |
915 |
200 |
|
Net cash flow from financing activities |
|
5,346 |
715 |
1,360 |
|
|
|
|
|
|
|
Net increase in cash and cash equivalents |
|
4,905 |
259 |
165 |
|
Cash and cash equivalents at beginning of period |
|
165 |
324 |
- |
|
Cash and cash equivalents at end of period |
|
5,070 |
583 |
165 |
Consolidated Statement of Changes in Shareholders' Equity
|
|
Share capital |
Share premium |
Re-organisation & reverse acquisition and other reserves |
Foreign Currency reserve |
Retained earnings |
Total |
|
|
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
|
At |
- |
- |
- |
- |
- |
- |
|
Changes in equity for period ended |
|
|
|
|
|
|
|
Total loss for the period |
- |
- |
- |
- |
(301) |
(301) |
|
Total comprehensive loss for the period |
- |
- |
- |
- |
(301) |
(301) |
|
Transactions with the owners Shares /Options issued |
- |
- |
- |
- |
- |
- |
|
At |
- |
- |
- |
- |
(301) |
(301) |
|
Changes in equity for 6 months ended |
|
|
|
|
|
|
|
Total loss for the period |
- |
- |
- |
- |
(463) |
(463) |
|
Total comprehensive loss for the period |
- |
- |
- |
- |
(463) |
(463) |
|
Transactions with the owners Shares /Options issued |
- |
- |
- |
- |
- |
- |
|
At |
- |
- |
- |
- |
(764) |
(764) |
|
Changes in equity for 6 months ended |
|
|
|
|
|
|
|
Total loss for the period |
|
|
|
|
(892) |
(892) |
|
Total comprehensive loss for the period |
- |
- |
- |
- |
(892) |
(892) |
|
Transactions with the owners Shares issued |
- |
- |
- |
- |
- |
- |
|
At |
- |
- |
- |
- |
(1,656) |
(1,656) |
|
Changes in equity for 6 months ended |
|
|
|
|
|
|
|
Total loss for the period |
- |
- |
- |
- |
(1,225) |
(1,225) |
|
Total comprehensive loss for the period |
- |
- |
- |
- |
(1,225) |
(1,225) |
|
Transactions with the owners Shares issued to Public |
90 |
4,247 |
- |
- |
- |
4,337 |
|
Investment In subsidiary |
281 |
14,726 |
(7,958) |
(44) |
- |
7,005 |
|
At |
371 |
18,973 |
(7,958) |
(44) |
(2,881) |
8,461 |
NOTES FORMING PART OF THE INTERIM FINANCIAL STATEMENTS
1. General information and basis of presentation
The Group's principal activity is as a European-focused, rare and orphan drug consulting services platform.
Based on the accounting standards under IFRS 3 and IFRS 10, the Group has determined that the entity with control of the combined group after the combination is Open Orphan DAC. It was therefore determined that reverse acquisition accounting is to be applied for presentation of the financial statements of the Company. This means that results reported for the period and comparable periods reflect those of Open Orphan DAC while the Balance Sheet reported for the period and comparable periods reflect those of the combined group with share capital reflecting the position of the ultimate parent
For information purposes, a pro forma statement of Comprehensive Income for the period and comparable periods for
The accounting policies applied by the Group in this financial information are the same as those applied by the Group in its financial statements for the year ended
The financial information presented herein does not constitute full statutory accounts under Section 434 of the Companies Act 2006 and was not subject to a formal review by the auditors. The financial information in respect of the year ended
2. Earnings per share
(a) Basic
Basic earnings per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period.
|
|
Unaudited |
|
Unaudited |
|
Audited |
|
|
6 months ended |
|
6 months ended |
|
|
|
|
30 June |
|
30 June |
|
31 December |
|
|
2019 €'000 |
|
2018 €'000 |
|
2018 €'000 |
|
Loss from continuing operations attributable to equity holders of the Company (€'000) |
(1,225) |
|
(463) |
|
(1,656) |
|
Total |
(1,225) |
|
(463) |
|
(1,656) |
|
|
|
|
|
|
|
|
Weighted-average Ordinary Shares in issue |
74,413,349 |
|
210,902 |
|
210,902 |
|
Basic and diluted loss per ordinary share (€ cent) |
(1.65) |
|
(219.73) |
|
(785.29) |
(b) Diluted
Due to the losses in the periods the effect of the share options and warrants noted below were considered to be anti-dilutive.
|
|
Unaudited |
|
Unaudited |
|
Audited |
|
|
6 months ended |
|
6 months ended |
|
|
|
|
30 June 2019 |
|
30 June 2018 |
|
31 December 2018 |
|
|
|
|
|
|
|
|
Potential dilutive ordinary shares: |
|
|
|
|
|
|
Weighted Options |
5,324,569 |
|
- |
|
- |
|
Weighted Warrants |
6,234,278 |
|
- |
|
- |
|
Total |
11,558,847 |
|
- |
|
- |
3. Proforma Statement of Comprehensive Income -
Per note 1, the schedule below reflected normalised Comprehensive Income for
|
|
|
Unaudited |
|
Unaudited |
|
Audited |
|
|
|
6 months ended |
|
6 months ended |
|
Year ended |
|
|
|
30 June |
|
30 June |
|
31 December |
|
|
|
2019 |
|
2018 |
|
2018 |
|
|
|
€'000 |
|
€'000 |
|
€'000 |
|
Continuing operations |
|
|
|
|
|
|
|
Revenue |
|
5,814 |
|
7,780 |
|
14,291 |
|
Administrative expenses |
|
(8,020) |
|
(8,045) |
|
(16,658) |
|
Operating (loss) |
|
(2,206) |
|
(265) |
|
(2,367) |
|
Depreciation and amortisation |
|
(702) |
|
(473) |
|
(935) |
|
EBITDA before exceptional items |
|
(1,504) |
|
208 |
|
(1,432) |
|
Finance income |
|
- |
|
- |
|
10 |
|
Finance costs |
|
(167) |
|
- |
|
- |
|
Gain/Impairment of Financial Asset Investments |
|
444 |
|
(360) |
|
(421) |
|
Share Options and Warrants Reserve |
|
(238) |
|
- |
|
- |
|
Impairment of Intangible Assets |
|
- |
|
- |
|
(2,232) |
|
Loss before income tax |
|
(2,167) |
|
(625) |
|
(5,010) |
|
Income tax credit |
|
378 |
|
33 |
|
235 |
|
Loss for the period |
|
(1,789) |
|
(592) |
|
(4,775) |
|
Loss attributable |
|
|
|
|
|
|
|
Owners of the parent |
|
(1,789) |
|
(592) |
|
(4,775) |
|
Loss for the period |
|
(1,789) |
|
(592) |
|
(4,775) |
|
Currency translation differences |
|
(3) |
|
(46) |
|
85 |
|
Total comprehensive loss for the period |
|
(1,792) |
|
(638) |
|
(4,690) |
4. Dividends
There were no dividends provided or paid during the six months.
5. Press
A copy of this announcement is available from the Company's website, being www.openorphan.com. If you would like to receive a hard copy of the interim report, please contact the
This information is provided by RNS, the news service of the
Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.
It is important for you to know that:
(a) none of the Content is, or is intended to be, general or personal advice
(b) the principal purpose of the Content is to provide factual information only and to comment on news;
(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;
(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and
(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.
In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.
FOR OUR FULL DISCLAIMER CLICK HERE